Your Domain Name Here are some guidelines for the Rayno Life Science Portfolio:
- Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak.
- Tools and diagnostics will be less volatile. ABAX, GPRO, ILMN.
- Raise cash or hedge by pruning winners or selling ETF’s. FBT,IBB and XBI.
- Weak stocks and/or laggards that need further review: BIIB, NKTR,SQNM.
- Next review will be post Q4 2010 earnings reports.